Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Recent clinical and preclinical research has suggested that cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have interactive effects on measures of cognition; however, the nature of these interactions is not yet fully characterized. To address this, we investigated the effects of Δ9-THC and CBD independently and in combination with proposed therapeutic dose ratios of 1:1 and 1:3 Δ9-THC:CBD in adult rhesus monkeys (n = 6) performing a stop signal task (SST). Additionally, the development of tolerance to the effects of Δ9-THC on SST performance was evaluated by determining the effects of acutely administered Δ9-THC (0.1-3.2 mg/kg), during a 24-day chronic Δ9-THC treatment period with Δ9-THC alone or in combination with CBD. Results indicate that Δ9-THC (0.032-0.32 mg/kg) dose-dependently decreased go success but did not alter go reaction time (RT) or stop signal RT (SSRT); CBD (0.1-1.0 mg/kg) was without effect on all measures and, when coadministered in a 1:1 dose ratio, did not exacerbate or attenuate the effects of Δ9-THC. When coadministered in a 1:3 dose ratio, CBD (1.0 mg/kg) attenuated the disruptive effects of 0.32 mg/kg Δ9-THC but did not alter the effects of other Δ9-THC doses. Increases in ED50 values for the effects of Δ9-THC on SST performance were apparent during chronic Δ9-THC treatment, with little evidence for modification of changes in sensitivity by CBD. These results indicate that CBD, when combined with Δ9-THC in clinically available dose ratios, does not exacerbate and, under restricted conditions may even attenuate, Δ9-THC's behavioral effects. (PsycINFO Database Record
Preclinical Pharmacology Laboratory.
David S
DS
Jacobs
Preclinical Pharmacology Laboratory.
Stephen J
SJ
Kohut
Center for Drug Discovery, Northeastern University.
Shan
S
Jiang
Center for Drug Discovery, Northeastern University.
Spyros P
SP
Nikas
Center for Drug Discovery, Northeastern University.
Alexandros
A
Makriyannis
Preclinical Pharmacology Laboratory.
Jack
J
Bergman
D000818:Animals; D002185:Cannabidiol / Q000008:administration & dosage*; D003071:Cognition / Q000187:drug effects; D013759:Dronabinol / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D008253:Macaca mulatta; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects*
D002185:Cannabidiol; D013759:Dronabinol
Handb Exp Pharmacol. 2005;(168):719-56
16596794
Br J Pharmacol. 2013 Dec;170(7):1365-73
23550724
Curr Pharm Des. 2014;20(25):4112-8
24001294
Brain Res. 2008 Jan 10;1188:157-64
18021759
Neuroscience. 2013 Apr 3;235:51-8
23333671
J Pharmacol Exp Ther. 2016 Apr;357(1):125-33
26826191
Transl Psychiatry. 2012 Mar 20;2:e94
22832859
Drug Alcohol Depend. 2002 May 1;66(3):265-73
12062461
Br J Pharmacol. 2013 Dec;170(7):1410-20
24106872
Biol Psychiatry. 2008 Dec 1;64(11):966-73
18589404
J Pharmacol Exp Ther. 1992 Aug;262(2):479-86
1323651
Drug Alcohol Depend. 1995 Nov;40(1):81-6
8746928
Trends Cogn Sci. 2008 Nov;12(11):418-24
18799345
Psychopharmacology (Berl). 2015 Jun;232(11):2007-16
25633093
J Neurosci Methods. 2009 Feb 15;177(1):67-72
18948136
Psychopharmacology (Berl). 1980;72(1):21-6
6258188
Epilepsia. 2014 Jun;55(6):783-6
24854149
J Am Vet Med Assoc. 1987 Apr 1;190(7):854-9
3570939
Curr Pharm Des. 2014;20(13):2126-37
23829358
Neuropsychol Rev. 2013 Jun;23(2):117-37
23129391
J Psychopharmacol. 2013 Jan;27(1):19-27
23042808
Neurochem Res. 2005 Aug;30(8):1037-43
16258853
Neuropsychopharmacology. 2006 Oct;31(10):2296-303
16572123
Drug Alcohol Depend. 2014 Jun 1;139:1-8
24703610
JAMA. 2002 Mar 6;287(9):1123-31
11879109
Psychopharmacology (Berl). 2011 Nov;218(2):443-57
21667074
Neuropsychopharmacology. 2003 Jul;28(7):1356-65
12784123
Br J Pharmacol. 2001 Oct;134(4):845-52
11606325
Lancet. 1998 Nov 14;352(9140):1611-6
9843121
Br J Psychiatry. 2010 Oct;197(4):285-90
20884951
Eur Neurol. 2014;72 Suppl 1:9-11
25278117
Clin Chem. 2011 Jan;57(1):66-75
21078841
Neuropharmacology. 2013 Dec;75:155-63
23924692
Behav Pharmacol. 1999 Sep;10(5):497-511
10780256
Ther Drug Monit. 2005 Dec;27(6):799-810
16306858
Exp Clin Psychopharmacol. 2011 Apr;19(2):154-72
21463073
Br J Pharmacol. 2008 Jan;153(2):199-215
17828291
Med Hypotheses. 2006;66(2):234-46
16209908
J Pharmacol Exp Ther. 2012 Sep;342(3):843-9
22718500
J Psychopharmacol. 2009 May;23(3):266-77
18719045
Br J Pharmacol. 2011 Mar;162(5):1060-73
21091643
Neuropharmacology. 2007 Mar;52(4):1079-87
17320118